$10.27 -$0.38 (-3.6%)

04:00 PM EDT on 07/16/19

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

CAPS Rating: 3 out of 5

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

Current Price $10.27 Mkt Cap $1.1B
Open $10.66 P/E Ratio 0.00
Prev. Close $10.65 Div. (Yield) $0.00 (0.0%)
Daily Range $10.18 - $10.66 Volume 182,675
52-Wk Range $9.56 - $16.08 Avg. Daily Vol. 10

Caps

How do you think NASDAQ:MNTA will perform against the market?

Add Stock to CAPS Watchlist

All Players

420 Outperform
29 Underperform
 

All-Star Players

82 Outperform
7 Underperform
 

Wall Street

11 Outperform
1 Underperform
 

Top NASDAQ:MNTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Kanga88 (23.85)
Submitted February 25, 2014

The business proposition and execution of Momenta has been solid, and it is a matter of time that the company will emerge as an innovative leader in the 21st century pharmaceutical industry. Born in the biotech labs of MIT, MNTA has been developing… More

rknapton (84.05)
Submitted August 22, 2013

Short. Pharma company whose revenues are getting slaughtered.

NASDAQ:MNTA VS S&P 500 (SPY)

Fools bullish on NASDAQ:MNTA are also bullish on:

Fools bearish on NASDAQ:MNTA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MNTA.

Recs

0
Member Avatar AsianMatter (< 20) Submitted: 4/2/2014 9:17:58 PM : Outperform Start Price: $11.52 NASDAQ:MNTA Score: -69.30

IZ

Recs

1
Member Avatar Kanga88 (23.85) Submitted: 2/25/2014 12:38:51 PM : Outperform Start Price: $17.51 NASDAQ:MNTA Score: -103.36

The business proposition and execution of Momenta has been solid, and it is a matter of time that the company will emerge as an innovative leader in the 21st century pharmaceutical industry. Born in the biotech labs of MIT, MNTA has been developing and accumulating advanced proprietary technology which allows it to produce generic drugs cheaper and hopefully purer than the originals. This will allow it to play leadership roles in the US where costs of medicine should account for 10% or so of the running away health costs!
As a bonus, it also has invested in R&D platforms for discovering new drugs, hopefully with breakthroughs in the future too.

Its path to successful commercializations has been full of obstacles, including legal challenges and competitive pressures. But only patient long term investors should invest in biotech stocks-- Caveat emptor !

Recs

0
Member Avatar manirg (< 20) Submitted: 12/24/2013 10:28:22 AM : Outperform Start Price: $17.71 NASDAQ:MNTA Score: -105.97

great potential , very undervalued

Leaderboard

Find the members with the highest scoring picks in MNTA.

Score Leader

anticitradeshort

anticitradeshort (33.27) Score: +256.24

The Score Leader is the player with the highest score across all their picks in MNTA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
anticitradeshort 33.27 4/20/2009 Underperform NS $10.50 -2.19% +254.05% +256.24 0 Comment
roth450 29.40 7/26/2010 Underperform NS $25.42 -59.60% +168.65% +228.25 0 Comment
shorttest4 33.40 3/8/2010 Underperform 5Y $15.44 -33.48% +162.32% +195.81 0 Comment
Oded270 < 20 8/31/2006 Underperform 3Y $16.35 -37.19% +144.42% +181.61 0 Comment
longtermgrowth09 31.64 12/17/2009 Underperform 5Y $10.98 -6.47% +170.71% +177.18 0 Comment
UltraContrarian 31.14 12/3/2009 Underperform 5Y $10.51 -2.28% +168.70% +170.98 0 Comment
BATZEM 41.61 9/28/2006 Underperform 3M $13.13 -21.78% +138.21% +159.99 0 Comment
fromnothing 40.12 9/27/2006 Underperform 1Y $12.89 -20.33% +138.46% +158.79 0 Comment
Made4WallStreet 68.95 12/29/2006 Underperform 1Y $15.70 -34.59% +123.97% +158.56 0 Comment
jtroiaffd 67.08 2/12/2007 Underperform 3M $16.29 -36.96% +121.02% +157.98 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackStifel 90.68 2/22/2018 Outperform NS $17.00 -39.59% +10.56% -50.15 0 Comment
TrackBarclaysCap 88.34 10/11/2016 Outperform NS $12.48 -17.71% +38.98% -56.69 0 Comment
TrackMaximGroup 65.06 5/9/2014 Outperform NS $10.49 -2.10% +59.69% -61.79 0 Comment
TrackWallachBeth 42.11 6/18/2013 Outperform NS $13.89 -26.06% +82.17% -108.24 0 Comment
TrackUBS 91.56 6/6/2013 Outperform NS $13.22 -22.31% +85.94% -108.25 0 Comment
TrackJGreenblatt 45.86 12/21/2011 Outperform 1Y $16.49 -32.93% +15.50% -48.43 12/13/2012 @ $11.06 1 Comment
TrackJimCramer 86.28 3/25/2011 Underperform 3W $14.56 -29.46% +128.28% +157.74 0 Comment
TrackOppenheimer < 20 11/20/2009 Outperform NS $11.17 -8.06% +171.22% -179.28 0 Comment
TrackCanaccord 62.55 11/19/2009 Outperform NS $10.47 +32.71% +18.01% +14.70 6/25/2012 @ $13.90 0 Comment
TrackSnow 29.72 9/30/2009 Outperform NS $10.61 -3.20% +191.06% -194.26 0 Comment
TrackDeutscheSec 82.17 9/19/2009 Outperform NS $11.71 -12.30% +179.73% -192.03 0 Comment
TrackWedbush 88.36 5/19/2009 Outperform NS $9.59 +7.09% +232.15% -225.06 0 Comment
TrackStanfordRes < 20 2/13/2009 Outperform NS $12.03 +20.78% +65.02% -44.24 4/17/2012 @ $14.53 0 Comment
TrackLeerinkSwan 97.27 1/5/2009 Outperform NS $11.26 -8.79% +229.54% -238.33 0 Comment
TrackRodmanRen < 20 4/29/2008 Outperform NS $15.57 -34.04% +123.09% -157.13 0 Comment
TrackBearStearns < 20 10/12/2007 Underperform NS $12.35 +17.65% -11.19% -28.84 4/17/2012 @ $14.53 0 Comment

Advertisement